Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study assessing BLU-808 in healthy volunteers

Next Previous
Search
Trial Profile

A phase I study assessing BLU-808 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BLU 808 (Primary)
  • Indications Chronic urticaria
  • Focus Adverse reactions

Most Recent Events

  • 01 May 2025 According to a Blueprint Medicines media release, data from the study were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) conference.
  • 13 Feb 2025 According to a Blueprint Medicines media release, data from this study will be presented at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress.
  • 12 Jan 2025 According to a Blueprint Medicines media release, detailed data will be presented at the J.P. Morgan conference on January 13, 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top